Download PDF
Semin Thromb Hemost 2023; 49(01): 076-078
DOI: 10.1055/s-0042-1756709
Commentary

The Case for Therapeutic-Intensity Anticoagulation in Patients with COVID-19-Associated Moderate Illness

Adam Cuker
1   Department of Medicine and Department of Pathology & Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
› Author Affiliations
› Further Information
   Permissions and Reprints

Thrombosis is common in patients with coronavirus disease 2019 (COVID-19)-associated moderate illness. A systematic review and meta-analysis reported venous thromboembolism in 7.9% of such patients, often despite the use of standard thromboprophylaxis.[1] Microvascular thrombosis associated with COVID-19 may contribute to other complications including critical illness, respiratory failure, and death. At the same time, increasing the intensity of anticoagulation in hospitalized patients with COVID-19 comes at the cost of increased bleeding.[2] As such, there has been intense interest in establishing the optimal intensity of anticoagulation in patients with COVID-19-associated moderate illness.



Publication History

Article published online:
29 September 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Nopp S, Moik F, Jilma B, Pabinger I, Ay C. Risk of venous thromboembolism in patients with COVID-19: a systematic review and meta-analysis. Res Pract Thromb Haemost 2020; 4 (07) 1178-1191
    CrossrefPubMedGoogle Scholar
  • 2 Jiménez D, García-Sanchez A, Rali P. et al. Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. Chest 2021; 159 (03) 1182-1196
    CrossrefPubMedGoogle Scholar
  • 3 Marcos-Jubilar M, Carmona-Torre F, Vidal R. et al; BEMICOP Investigators. Therapeutic versus prophylactic bemiparin in hospitalized patients with nonsevere COVID-19 pneumonia (BEMICOP study): an open-label, multicenter, randomized, controlled trial. Thromb Haemost 2022; 122 (02) 295-299
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Sholzberg M, Tang GH, Rahhal H. et al; RAPID trial investigators. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ 2021; 375 (2400): n2400
    CrossrefPubMedGoogle Scholar
  • 5 Lawler PR, Goligher EC, Berger JS. et al; ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators. Therapeutic anticoagulation with heparin in noncritically ill patients with COVID-19. N Engl J Med 2021; 385 (09) 790-802
    CrossrefPubMedGoogle Scholar
  • 6 Spyropoulos AC, Goldin M, Giannis D. et al; HEP-COVID Investigators. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial. JAMA Intern Med 2021; 181 (12) 1612-1620
    CrossrefPubMedGoogle Scholar
  • 7 Lopes RD, de Barros E Silva PGM, Furtado RHM. et al; ACTION Coalition COVID-19 Brazil IV Investigators. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet 2021; 397 (10291): 2253-2263
    CrossrefPubMedGoogle Scholar
  • 8 Cuker A, Tseng EK, Nieuwlaat R. et al. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients. Blood Adv 2022 bloodadvances.2022007561
    PubMedGoogle Scholar
  • 9 Cuker A, Tseng EK, Nieuwlaat R. et al. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Adv 2021; 5 (03) 872-888
    CrossrefPubMedGoogle Scholar
  • 10 National Institutes of Health. The COVID-19 Treatment Guidelines Panel's statement on anticoagulation in hospitalized patients with COVID-19; 2022. Accessed 31 May 2022 at: https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-anticoagulation-in-hospitalized-patients/
    PubMedGoogle Scholar
  • 11 ISTH draft guidelines for antithrombotic treatment in COVID-19. Accessed 31 May 2022 at: https://cdn.ymaws.com/www.isth.org/resource/resmgr/guidance_and_guidelines/covid19/covid-19-draft_for_comment.pdf
    PubMedGoogle Scholar
  • 12 Barnes GD, Burnett A, Allen A. et al. Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum. J Thromb Thrombolysis 2022; 54 (02) 197-210
    CrossrefPubMedGoogle Scholar
  • 13 Sadeghipour P, Talasaz AH, Rashidi F. et al; Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. JAMA 2021; 325 (16) 1620-1630
    CrossrefPubMedGoogle Scholar
  • 14 Perepu US, Chambers I, Wahab A. et al. Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial. J Thromb Haemost 2021; 19 (09) 2225-2234
    CrossrefPubMedGoogle Scholar